Role of micro-RNAs in breast cancer surgery

McAnena, Peter; Lowery, Aoife; Kerin, Michael J.

doi:10.1002/bjs.10790

Cited by 13 publications

(8 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the same way, McAnena et al. underlined the synergistic anticancer effects of piRNA-36 with paclitaxel and doxorubicin [111] . Finally, Gavgani et al.…”

Section: Role Of Ncrnas In Breast Cancersmentioning

confidence: 97%

Overview of non-coding RNAs in breast cancers

Dabi¹,

Bendifallah²,

Suisse³

et al. 2022

Translational Oncology

View full text Add to dashboard Cite

“…In the same way, McAnena et al. underlined the synergistic anticancer effects of piRNA-36 with paclitaxel and doxorubicin [111] . Finally, Gavgani et al.…”

Section: Role Of Ncrnas In Breast Cancersmentioning

confidence: 97%

Overview of non-coding RNAs in breast cancers

Dabi¹,

Bendifallah²,

Suisse³

et al. 2022

Translational Oncology

View full text Add to dashboard Cite

“…MiRNA is a non-coding small RNA of about 19–22 nt encoded by the cell genome of eukaryotic organisms. It regulates gene expression by promoting the degradation of target mRNA or inhibiting mRNA translation, ultimately affecting the development, proliferation, differentiation, and apoptosis of cells [51] . The mechanism of miRNA is to combine with miRNA-induced silencing complex(miRISC) on the target mRNA to form an asymmetric RISC.…”

Section: Gene Therapy Drugsmentioning

confidence: 99%

Applications and developments of gene therapy drug delivery systems for genetic diseases

Pan

Veroniaina

et al. 2021

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Genetic diseases seriously threaten human health and have always been one of the refractory conditions facing humanity. Currently, gene therapy drugs such as siRNA, shRNA, antisense oligonucleotide, CRISPR/Cas9 system, plasmid DNA and miRNA have shown great potential in biomedical applications. To avoid the degradation of gene therapy drugs in the body and effectively deliver them to target tissues, cells and organelles, the development of excellent drug delivery vehicles is of utmost importance. Viral vectors are the most widely used delivery vehicles for gene therapy in vivo and in vitro due to their high transfection efficiency and stable transgene expression. With the development of nanotechnology, novel nanocarriers are gradually replacing viral vectors, emerging superior performance. This review mainly illuminates the current widely used gene therapy drugs, summarizes the viral vectors and non-viral vectors that deliver gene therapy drugs, and sums up the application of gene therapy to treat genetic diseases. Additionally, the challenges and opportunities of the field are discussed from the perspective of developing an effective nano-delivery system.

show abstract

“…Recently circulating miRNAs using extraction miRNA from peripheral blood instead from tissue show great promise in contributing to the diagnosis, prognosis, and evaluation of response to therapy and treatment of breast cancer [16][17][18]. miRNAs are constant in circulation and can be measured relatively simply and inexpensively (using real-time quantitative reverse transcriptase PCR; RT-qPCR) [19][20][21][22].…”

Section: Aimentioning

confidence: 99%

Using miR-125b in the Prediction of Aromatase Inhibitors Resistance in Metastatic Breast Cancer

Zedain

Badrway

Refaat

et al. 2020

JCTI

View full text Add to dashboard Cite

Background: Several studies investigated the miRNAs in cancer trying to assess the prognosis or to predict the response to certain treatment .One of these miRNAs are miR 125b , it was suggested by previous results as a good marker for prediction of aromatase inhibitors (AI) response. So, this study was conducted to assess the value using miRNA125b as a predictive factor to AI response. Patients and Methods: A total of 90 patients of postmenopausal HR+ve metastatic breast cancer who attended to medical oncology department outpatient’s clinic in SECI, Assiut university Egypt, from May 2017 to September 2018. Patients presented with metastasis at diagnosis as well as patients who relapsed only after 3 years of adjuvant hormonal treatment with SERM were included. All patients received AI as first line treatment for metastatic, miRNA 125b was isolated from peripheral blood samples and measured by using (q PCR).The response of patients was assessed by RECIST criteria and correlated with its expression levels. Results: Expression of the miR125-b was significantly higher in patients than control p= 0.000. However, no significant difference in its expression between those with single of multiple metastases or even between the site of metastases. We didn’t find also any significant difference in response p=0.648 and survival either PFS p=0.406 or OS p=0.384 between those patients with high expression vs. low expression. Conclusion: Our results suggest that miR125b could be used as a diagnostic marker as it is significantly increased in patients than control. However, we don’t recommend using miR125b as a marker to predict the AI resistance as further studies with large sample size are needed to confirm these results.

show abstract

Role of micro-RNAs in breast cancer surgery

Abstract: Background: The management of breast cancer has changed dramatically in the molecular era. Micro-RNAs can contribute to multiple facets of cancer surgery.

Cited by 13 publications

References 126 publications

Overview of non-coding RNAs in breast cancers

Overview of non-coding RNAs in breast cancers

Applications and developments of gene therapy drug delivery systems for genetic diseases

Using miR-125b in the Prediction of Aromatase Inhibitors Resistance in Metastatic Breast Cancer

Contact Info

Product

Resources

About